Welcome!

News Feed Item

The Leukemia & Lymphoma Society Awards $12.6 Million in Research Grants in Six Critical Areas of Unmet Medical Need

WHITE PLAINS, N.Y., Jan. 6, 2014 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) has awarded 21 new grants representing a total investment of $12.6 million to tackle six areas of high unmet medical need in the blood cancers.

In response to requests for proposals (RFPs) from researchers in these six critical areas, LLS has awarded these grants under its Translational Research Program (TRP), an initiative designed to help accelerate the movement of promising discoveries from the lab to the clinic. Each grant is for a three-year duration with a total value of $600,000.

The RFPs mark LLS's proactive approach to addressing the challenge of improving outcomes for cancer patients with particularly urgent needs. The focus of the TRP grants, and the grant recipients are as follows:

  • New immunotherapeutics for patients with acute myelogenous leukemia (AML):

    • David Avigan, M.D., Beth Israel Deaconess Medical Center. Clinical trial evaluating DC/AML fusion vaccine with PD1 blockade
    • Stephen Forman, M.D., Beckman Research Institute of the City of Hope. Adoptive therapy for AML using CAR123-transduced T cells
    • Dean Lee, M.D., Ph.D., University of Texas MD Anderson Cancer Center. Targeting NK cell immunotherapy against AML stem cells.
    • Ulrich Steidl, M.D., Ph.D., Albert Einstein College of Medicine of Yeshiva University. Targeting IL-1 receptor accessory protein in malignant stem cells in AML
    • Chengcheng Zhang, Ph.D., UT Southwestern Medical Center. Blocking immune inhibitory receptor LAIR1 for AML treatment

  • Novel therapeutics for patients with non-cutaneous T-cell malignancies:

    • Thomas Loughran, M.D., The Pennsylvania State University College of Medicine. Targeting JAK/STAT and NF-kB pathways in large granular lymphocytic leukemia
    • David Wiest, Ph.D., Fox Chase Cancer Center, Role of ER stress responses in pathogenesis and treatment of T-cell acute lymphocytic leukemia
    • Javeed Iqbal, Ph.D., Board of Regents of the University of Nebraska Medical Center. Somatic mutations and epimutations in peripheral T-cell lymphoma

  • Introduction of novel agents in the treatment of patients with diffuse large B-cell lymphom(DLBCL) and mantle cell lymphoma(MCL):

    • Robert Baiocchi, M.D., Ph.D., The Ohio State University Research Foundation. Targeting PRMT5 expression in DLBCL and MCL
    • Leandro Cerchietti, M.D., Joan & Sanford I. Weill Cornell Medical College of Cornell University. EIF4E targeted therapy in lymphomas
    • Ari Melnick, M.D., Joan & Sanford I. Weill Cornell Medical College of Cornell University. Rational translational of EZH2 targeted therapy
    • Alessandra Pernis, M.D., The Hospital for Special Surgery. Novel signaling pathways in DLBCL
    • James Rubenstein, M.D., Ph.D., The Regents of the University of California, San Francisco. Molecular targets for high-risk primary CNS lymphoma
    • John Timmerman, M.D., The Regents of the University of California, Los Angeles. PD-1/PD-L1 blockade plus kinase inhibitor therapies for B cell lymphomas

  • Therapies for patients with myelodysplastic syndromes(MDS) who have failed hypomethylating agents:

    • Maria Figueroa, M.D., University of Michigan Health System, Epigenetic markers of sensitivity and resistance to hypomethylating agents

  • Therapies for new targets such as bromodomains, methylation and other epigenetic approaches for patients with high-risk myeloma:

    • Xiu-Bao Chang, Ph.D., Mayo Clinic Arizona. Immunomodulatory drugs target cereblon and its downstream substrates
    • Constantine Mitsiades, M.D., Ph.D., Dana-Farber Cancer Institute. Individualizing myeloma treatment with BET bromodomain inhibitors

  • Research that addresses long-term and late effects of blood cancer therapies:

    • Mukta Arora, M.D., Regents of the University of Minnesota, Twin Cities. Biomarkers of frailty and its impact on geriatric HSCT outcomes
    • Seth Corey, M.D., Northwestern UniversityChicago campus. Development of an oral anti-fibrotic drug for patients with myelofibrosis
    • Patricia Gallagher, Ph.D., Wake Forest University Health Sciences. Prevention of doxorubicin-induced cardiotoxic late effects by Ang-(1-7)
    • Matthew Matasar, M.D., Memorial Sloan-Kettering Cancer Center. Tissue and functional assessment of myocardial injury in HL survivors

LLS also announced the awarding of an additional 20 TRP grants not related to the RFPs, totaling $11.4 million, to scientists working in other areas of blood cancer research.

"The translation of research discoveries in the laboratory to the patient's bedside for the treatment of blood cancer is a central part of the mission of LLS," said Lee Greenberger, Ph.D., LLS chief scientific officer. "By taking a strategic, proactive approach, LLS is directing grant funds with the intent to accelerate the advancement of breakthrough therapies and provide the best quality of life for our patients."

About The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society ® (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, multiple myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.  

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET.

Contact: Andrea Greif
(914) 821-8958
[email protected] 
www.LLS.org

 

SOURCE The Leukemia & Lymphoma Society

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
What if you could build a web application that could support true web-scale traffic without having to ever provision or manage a single server? Sounds magical, and it is! In his session at 20th Cloud Expo, Chris Munns, Senior Developer Advocate for Serverless Applications at Amazon Web Services, will show how to build a serverless website that scales automatically using services like AWS Lambda, Amazon API Gateway, and Amazon S3. We will review several frameworks that can help you build serverle...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
After more than five years of DevOps, definitions are evolving, boundaries are expanding, ‘unicorns’ are no longer rare, enterprises are on board, and pundits are moving on. Can we now look at an evolution of DevOps? Should we? Is the foundation of DevOps ‘done’, or is there still too much left to do? What is mature, and what is still missing? What does the next 5 years of DevOps look like? In this Power Panel at DevOps Summit, moderated by DevOps Summit Conference Chair Andi Mann, panelists l...
The essence of cloud computing is that all consumable IT resources are delivered as services. In his session at 15th Cloud Expo, Yung Chou, Technology Evangelist at Microsoft, demonstrated the concepts and implementations of two important cloud computing deliveries: Infrastructure as a Service (IaaS) and Platform as a Service (PaaS). He discussed from business and technical viewpoints what exactly they are, why we care, how they are different and in what ways, and the strategies for IT to transi...
Culture is the most important ingredient of DevOps. The challenge for most organizations is defining and communicating a vision of beneficial DevOps culture for their organizations, and then facilitating the changes needed to achieve that. Often this comes down to an ability to provide true leadership. As a CIO, are your direct reports IT managers or are they IT leaders? The hard truth is that many IT managers have risen through the ranks based on their technical skills, not their leadership abi...
Web Real-Time Communication APIs have quickly revolutionized what browsers are capable of. In addition to video and audio streams, we can now bi-directionally send arbitrary data over WebRTC's PeerConnection Data Channels. With the advent of Progressive Web Apps and new hardware APIs such as WebBluetooh and WebUSB, we can finally enable users to stitch together the Internet of Things directly from their browsers while communicating privately and securely in a decentralized way.
All organizations that did not originate this moment have a pre-existing culture as well as legacy technology and processes that can be more or less amenable to DevOps implementation. That organizational culture is influenced by the personalities and management styles of Executive Management, the wider culture in which the organization is situated, and the personalities of key team members at all levels of the organization. This culture and entrenched interests usually throw a wrench in the work...
Keeping pace with advancements in software delivery processes and tooling is taxing even for the most proficient organizations. Point tools, platforms, open source and the increasing adoption of private and public cloud services requires strong engineering rigor - all in the face of developer demands to use the tools of choice. As Agile has settled in as a mainstream practice, now DevOps has emerged as the next wave to improve software delivery speed and output. To make DevOps work, organization...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
What sort of WebRTC based applications can we expect to see over the next year and beyond? One way to predict development trends is to see what sorts of applications startups are building. In his session at @ThingsExpo, Arin Sime, founder of WebRTC.ventures, will discuss the current and likely future trends in WebRTC application development based on real requests for custom applications from real customers, as well as other public sources of information,
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 20th Cloud Expo, which will take place on June 6-8, 2017 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 add...
Historically, some banking activities such as trading have been relying heavily on analytics and cutting edge algorithmic tools. The coming of age of powerful data analytics solutions combined with the development of intelligent algorithms have created new opportunities for financial institutions. In his session at 20th Cloud Expo, Sebastien Meunier, Head of Digital for North America at Chappuis Halder & Co., will discuss how these tools can be leveraged to develop a lasting competitive advanta...
TechTarget storage websites are the best online information resource for news, tips and expert advice for the storage, backup and disaster recovery markets. By creating abundant, high-quality editorial content across more than 140 highly targeted technology-specific websites, TechTarget attracts and nurtures communities of technology buyers researching their companies' information technology needs. By understanding these buyers' content consumption behaviors, TechTarget creates the purchase inte...
With the introduction of IoT and Smart Living in every aspect of our lives, one question has become relevant: What are the security implications? To answer this, first we have to look and explore the security models of the technologies that IoT is founded upon. In his session at @ThingsExpo, Nevi Kaja, a Research Engineer at Ford Motor Company, will discuss some of the security challenges of the IoT infrastructure and relate how these aspects impact Smart Living. The material will be delivered i...
In his session at @ThingsExpo, Eric Lachapelle, CEO of the Professional Evaluation and Certification Board (PECB), will provide an overview of various initiatives to certifiy the security of connected devices and future trends in ensuring public trust of IoT. Eric Lachapelle is the Chief Executive Officer of the Professional Evaluation and Certification Board (PECB), an international certification body. His role is to help companies and individuals to achieve professional, accredited and worldw...